Exelixis, Inc. Hits New 52-Week High of $53.81, Up 137.6%

Exelixis, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 53.81 on June 10, 2026. This achievement underscores the company's robust performance over the past year, with a remarkable 137.6% increase compared to the S&P 500's 20.34% gain during the same period. The company's financial metrics reflect strong fundamentals, including a price-to-earnings (P/E) ratio of 14.00 and a return on equity (ROE) of 36.94%. Exelixis has demonstrated healthy growth, with net sales increasing at an annual rate of 18.63% and a net profit growth of 31.86%. The company has also reported positive results for three consecutive quarters, showcasing its operational strength. With a market capitalization of USD 10,786 million and a debt-equity ratio of -0.48, Exelixis stands out as a net-debt-free entity. Its operating cash flow reached an impressive USD 924.67 million, further solidifying its financial position. The stock's performance, coupled with high institutional holdings at 100%, indicates a strong market presence and investor confidence in Exelixis, Inc.